Data cohorts in the neuGRID2 environment
| To serve scientific research communities neuGRID2 is offering different datasets with different access rights. NeuGRID2 is registered on the Registry of Research Data Repositories (re3data.org).
NeuGRID offers two main access rights:
|
 |
OASIS
|
 |
|
OPEN-ACCESS |
|
OASIS (Open Access Series of Imaging Studies) consists of (I) a cross-sectional collection of 416 subjects aged 18 to 96. 100 of the included subjects over the age of 60 have been clinically diagnosed with very mild to moderate Alzheimer0s disease (AD). (II) A longitudinal collection of 160 subjects aged 60 to 96. Each subject was scanned on two or more visits, separated by at least one year for a total of 373 imaging sessions. For each subject 3 or 4 individual T1-weighted MRI scans obtained in single scan sessions are included. The subjects are all right-handed and include both men and women. 72 subjects were non demented. 64 were demented, including 51 individuals with mild to moderate Alzheimer’s disease. |
I-ADNI
|
 |
|
OPEN-ACCESS |
|
I-ADNI is a cross sectional study and consists of 262 patients with subjective memory impairment, mild cognitive impairment, Alzheimer’s dementia and frontotemporal dementia enrolled in 7 Italian centers. Few cognitively healthy elderly controls were also included. This study has provided standardization of MRI acquisition and imaging marker collection across different Italian clinical units and equipment. This is a mandatory step to the implementation of imaging biomarkers in clinical routine for early and differential diagnosis. MRI site qualification and MP-RAGE quality assessment was applied following the ADNI-1 procedures. |
PHARMACOG – MCI Patients
|
 |
|
OPEN-ACCESS |
|
PHARMACOG (alias E-ADNI) marks the start of the most ambitious European project for tackling bottlenecks in Alzheimer’s disease research and drug discovery. PharmaCOG is short for “Prediction of cognitive properties of new drug candidates for neurodegenerative diseases in early clinical development”. It is a partnership of 32 academic and industry actors from 7 countries, co-ordinated by GlaxoSmithKline R&D and the Universitté de la Méditerranée, started its activities on January 1, 2010 thanks to significant funding (EUR 20.2 million) from the Innovative Medicines Initiative. 147 MCI patients are studied along 7 time points (i.e. BSL, T06, T12, T18, T24, T30 and T36). Please cite the investigators list when using PHARMACOG for scientific purposes. |
PHARMACOG – DTI – Reproducibility
|
 |
|
OPEN-ACCESS |
|
50 healthy Caucasian subjects (50-80 years) were scanned in two sessions at least a week apart in 10 clinical 3T scanners distributed in Europe (5 subjects per site). Each acquisition session has one diffusion acquisition (2x2x2 mm3), b-700 s/mm2, 5 b0 and 30 diffusion weighted volumes. Scanner vendors were Siemens (Allegra, TrioTim, Verio, Skyra, MRBiograph), Philips (Achieva) and GE (Signa HDxt). The 100 raw diffusion datasets are available. Images are anonymous. Please cite the investigators list when using PHARMACOG for scientific purposes. |
PHARMACOG – Morphometry – Reproducibility
|
|
|
OPEN-ACCESS |
|
40 healthy Caucasian subjects (50-80 years) were scanned in two sessions at least a week apart in 8 clinical 3T scanners distributes in Europe (5 subjects per site). Each acquisition session has two 3D T1-wighted images (1x1x1 mm3). Scanner vendors were Siemens (Allegra, TrioTim, Verio, Skyra, MRBiograph), Philips (Achieva) and GE (Signa HDxt). Two volumes were not acquired giving a total of 158 brain volumes available. Images are anonymous. Please cite the investigators list when using PHARMACOG for scientific purposes. |
PHARMACOG – resting – state – fMRI – Reproducibility
|
|
|
OPEN-ACCESS |
|
65 healthy Caucasian subjects (50-80 years) were scanned in two sessions at least a week apart in 13 clinical 3T scanners distributes in Europe (5 subjects per site). Each acquisition session includes the acquisition of two 3D MPRAGE structural images and one resting state BOLD fMRI acquisition (3x3x3 mm3, TR=2.7s, TE=30ms, 200 volumes). Scanner vendors were Siemens (Allegra, TrioTim, Verio, Skyra, MRBiograph), Philips (Achieva) and GE (Signa HDxt, Discovery MR750). The anonimizied nifti raw datasets for the 130 acquisition sessions are available. Please cite the investigators list when using PHARMACOG for scientific purposes. |
ARWIBO
|
 |
|
OPEN-ACCESS |
|
This dataset is very useful to make comparison between the CTR subjects and MCI as well as patients in the AD stage. ARWIBO is a cross-sectional dataset including data from more than 2700 patients enrolled in Brescia and nearby areas. The database contains data of healthy elderly Controls (CTR), individual with Mild Cognitive Impairment (MCI), and patients with Alzheimer’s disease. Images are both structural images weighted in T1 and T2 (at 1.0T or 1.5T) as well as PET scans. All data are de-identified. |
EDSD
|
 |
|
OPEN-ACCESS |
|
The EDSD data include 471 Diffusion Tensor Imaging (DTI) and 471 structural MRI scans (MPRAGE) from patients with Alzheimer’s Disease (AD), Mild Cognitive Impairment (MCI) and Healthy Elderly subjects. EDSD is a cross-sectional multicenter study. |
VITA
|
 |
|
OPEN-ACCESS |
|
VITA is a population based cohort-study of all 75-years old inhabitant of a geographically defined area of Vienna. VITA is composed by 606 subjects followed longitudinally for 4 years. Recruitment took place between May 2000 and October 2002. The primary focus of the VITA work group was to establish a prospective age cohort for evaluation of prognostic criteria for the development of AD. |
WMH-AD
|
 |
|
OPEN-ACCESS |
|
WMH-AD is interested in white matter hyperintensities (WMH) and at least 50% of patients with AD have been documented with this pathological change. White mater provides anatomic connections among brain regions and severe WMHs burden may contribute to cognitive impairment. WMH-AD is composed by 92 subjects (30 men and 62 women) followed cross-sectionally. The patients underwent to the following imaging scans: T13D, FLAIR and DTI (61 gradient directions) at 3.0 Tesla. |